7 VC firms investing in biotech & life sciences and agetech & longevity at the Seed stage.
F4 Fund tracks 7 VC firms that actively invest in biotech & life sciences + agetech & longevity at the Seed stage, with check sizes ranging from $200K – $4M (median: $1.1M – $1.1M). As of August 2026, and 100% lead or co-lead rounds. Rankings are based on F4's proprietary analysis of 1,556+ researched VC firms, scored by data completeness, portfolio depth, investment recency, and stage alignment.
| # | Firm | Check Size | Portfolio | Leads? | Activity | Decision | Intro |
|---|---|---|---|---|---|---|---|
| 1 | ▶ AGE1 Funding the next generation of contrarian founders building breakthrough longevity biotech companies. We invest in the transition from sickcare to healthcare by extending healthy lifespan and preventing age-related disease. | $500K – $4M | 24 | Leads | Active | N/A | N/A |
| 2 | ▶ The Longevity Fund Longevity is a completely new industry within biotech requiring founders who can think differently. Mission-oriented, founder-led companies with unconventional backgrounds will prove most effective at bringing the first longevity drugs to market and extending human healthy lifespan. The field is at a critical inflection point where we will either breakthrough to mainstream or get silo'd in a funding winter. San Francisco | $250K – $3M | 23 | Leads | Active | ~2 wks | Open |
| 3 | ▶ Springbank Collective We invest in mission-critical infrastructure serving women and working families. Many essential systems have been dismissed as too complex or too human to solve, but technology and AI advances make transformation possible. This is a $1 trillion opportunity and generational economic growth driver. New York | $250K – $2M | 36 | Leads | Active | ~2 wks | Open |
| 4 | ▶ The Helm Women receive only 2% of venture capital despite female-founded startups delivering 2x return per dollar vs. all-male teams. The Helm invests in game-changing, undervalued companies at seed stage founded by women, providing not just capital but operational support and ecosystem access. New York | $250K – $1.5M | 27 | Leads | Active | ~2 wks | Open |
| 5 | ▶ AENU Rewriting the VC rulebook to deliver high returns with high impact. We invest in founders building climate and social impact technologies with intentional, measurable, net-positive outcomes at meaningful scale. | $1M – $4M | 14 | Leads | Active | N/A | N/A |
| 6 | ▶ Ada Ventures Backing the best founders, not just the best-connected. We assess founders on their qualities, not CV or past experience. We focus on founders building solutions for climate equity, economic empowerment, and healthy ageing. London | $250K – $1M | 30 | Leads | Active | N/A | N/A |
| 7 | ▶ TheoryForge Operator-led fund investing in ambitious founders building transformative AI applications. We partner with technical founders who understand AI/ML deeply and are solving real customer problems with capital efficiency. Great product is always the best marketing. | $200K – $500K | 38 | Both | Active | ~2 wks | Req'd |
Investors on this page also frequently invest in these sectors
What other stages do these firms also invest in?
What other sectors do these firms also invest in?
Firms that frequently co-invest with investors on this page
F4 Fund tracks 7 VC firms that actively invest in biotech & life sciences + agetech & longevity at the Seed stage. These firms are ranked using a composite score that weighs data completeness (30%), portfolio depth (30%), investment recency (25%), and stage alignment (15%).
Based on F4's analysis, the median check size for seed biotech & life sciences + agetech & longevity investors is $1.1M – $1.1M, with a full range from $200K – $4M. The distribution breaks down as: 1 firms in the <$500K range, 2 firms in the $500K-$1M range, 2 firms in the $1M-$2M range, 2 firms in the $2M-$5M range.
Among the 7 firms tracked, 100% lead or co-lead rounds. Founders seeking a lead investor should filter for firms marked "Leads" or "Both" in the rankings table above. Lead investors typically set deal terms and anchor the round.
The best seed biotech & life sciences + agetech & longevity investors combine domain expertise with an active portfolio in the space. Among these firms, 25% prefer warm introductions, and the average firm has 27 portfolio companies. Look for firms whose check size matches your raise, whose stage preference aligns with yours, and who have a track record of supporting companies in your sector through multiple growth phases.
Firm profiles are continuously updated through F4's research pipeline, which combines LLM-powered web research, portfolio analysis, and transcript extraction. The ranking data refreshes every 12 hours. Editorial analysis is reviewed weekly. Individual firm profiles are re-researched on a 30-day cycle or when new information surfaces.